

Eric P Hoffman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/703519/publications.pdf>

Version: 2024-02-01

421
papers

32,795
citations

4658
85
h-index

5120
166
g-index

478
all docs

478
docs citations

478
times ranked

26391
citing authors

#	ARTICLE	IF	CITATIONS
1	Influence of β^2 adrenergic receptor genotype on longitudinal measures of forced vital capacity in patients with Duchenne muscular dystrophy. <i>Neuromuscular Disorders</i> , 2022, 32, 150-158.	0.6	3
2	Acute serum protein and cytokine response of single dose of prednisone in adult volunteers. <i>Steroids</i> , 2022, 178, 108953.	1.8	4
3	Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy. <i>JAMA Network Open</i> , 2022, 5, e2144178.	5.9	31
4	A mouse model of inherited choline kinase β^2 -deficiency presents with specific cardiac abnormalities and a predisposition to arrhythmia. <i>Journal of Biological Chemistry</i> , 2022, 298, 101716.	3.4	4
5	Mechanism of action and therapeutic route for a muscular dystrophy caused by a genetic defect in lipid metabolism. <i>Nature Communications</i> , 2022, 13, 1559.	12.8	9
6	Genetic modifiers of upper limb function in Duchenne muscular dystrophy. <i>Journal of Neurology</i> , 2022, 269, 4884-4894.	3.6	2
7	Long-Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne Muscular Dystrophy. <i>Journal of Neuromuscular Diseases</i> , 2022, 9, 493-501.	2.6	31
8	The Influence of Metabolic Syndrome Risk Factors on Carotid Intima Media Thickness in Children. <i>Global Pediatric Health</i> , 2021, 8, 2333794X2098745.	0.7	3
9	Biomarker-focused multi-drug combination therapy and repurposing trial in mdx mice. <i>PLoS ONE</i> , 2021, 16, e0246507.	2.5	10
10	Concerns Regarding Therapeutic Implications of Very Low β^2 -Level Dystrophin. <i>Annals of Neurology</i> , 2021, 90, 176-176.	5.3	3
11	Elevation of fast but not slow troponin I in the circulation of patients with Becker and Duchenne muscular dystrophy. <i>Muscle and Nerve</i> , 2021, 64, 43-49.	2.2	13
12	Human muscle stem cells are refractory to aging. <i>Aging Cell</i> , 2021, 20, e13411.	6.7	18
13	Exon-Skipping in Duchenne Muscular Dystrophy. <i>Journal of Neuromuscular Diseases</i> , 2021, 8, S343-S358.	2.6	34
14	Blunted circadian cortisol in children is associated with poor cardiovascular health and may reflect circadian misalignment. <i>Psychoneuroendocrinology</i> , 2021, 129, 105252.	2.7	6
15	Validation of Chemokine Biomarkers in Duchenne Muscular Dystrophy. <i>Life</i> , 2021, 11, 827.	2.4	6
16	Effects of Chronic, Maximal Phosphorodiamidate Morpholino Oligomer (PMO) Dosing on Muscle Function and Dystrophin Restoration in a Mouse Model of Duchenne Muscular Dystrophy. <i>Journal of Neuromuscular Diseases</i> , 2021, 8, S369-S381.	2.6	1
17	A Dystrophin Exon-52 Deleted Miniature Pig Model of Duchenne Muscular Dystrophy and Evaluation of Exon Skipping. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13065.	4.1	9
18	Absolute quantification of dystrophin protein in human muscle biopsies using parallel reaction monitoring (PRM). <i>Journal of Mass Spectrometry</i> , 2020, 55, e4437.	1.6	13

#	ARTICLE	IF	CITATIONS
19	TCTEX1D1 is a genetic modifier of disease progression in Duchenne muscular dystrophy. <i>European Journal of Human Genetics</i> , 2020, 28, 815-825.	2.8	36
20	A long-read RNA-seq approach to identify novel transcripts of very large genes. <i>Genome Research</i> , 2020, 30, 885-897.	5.5	29
21	Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study. <i>PLoS Medicine</i> , 2020, 17, e1003222.	8.4	41
22	Novel mutation identification and copy number variant detection via exome sequencing in congenital muscular dystrophy. <i>Molecular Genetics & Genomic Medicine</i> , 2020, 8, e1387.	1.2	3
23	Disruption of a key ligand-H-bond network drives dissociative properties in vamorolone for Duchenne muscular dystrophy treatment. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 24285-24293.	7.1	26
24	Exposure-Response Analysis of Vamorolone (VBP15) in Boys With Duchenne Muscular Dystrophy. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 1385-1396.	2.0	8
25	Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping. <i>JAMA Neurology</i> , 2020, 77, 982.	9.0	169
26	Serum biomarkers associated with baseline clinical severity in young steroid-naïve Duchenne muscular dystrophy boys. <i>Human Molecular Genetics</i> , 2020, 29, 2481-2495.	2.9	19
27	The discovery of dystrophin, the protein product of the Duchenne muscular dystrophy gene. <i>FEBS Journal</i> , 2020, 287, 3879-3887.	4.7	27
28	MicroRNA Profiling in Adipose Before and After Weight Loss Highlights the Role of miR-223 and the NLRP3 Inflammasome. <i>Obesity</i> , 2020, 28, 570-580.	3.0	11
29	Muscle Weakness in Myositis: MicroRNA-Mediated Dystrophin Reduction in a Myositis Mouse Model and Human Muscle Biopsies. <i>Arthritis and Rheumatology</i> , 2020, 72, 1170-1183.	5.6	26
30	Genetic modifiers of respiratory function in Duchenne muscular dystrophy. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 786-798.	3.7	36
31	Causes of clinical variability in Duchenne and Becker muscular dystrophies and implications for exon skipping therapies. <i>Acta Myologica</i> , 2020, 39, 179-186.	1.5	7
32	Title is missing!. , 2020, 17, e1003222.		0
33	Title is missing!. , 2020, 17, e1003222.		0
34	Title is missing!. , 2020, 17, e1003222.		0
35	Title is missing!. , 2020, 17, e1003222.		0
36	Title is missing!. , 2020, 17, e1003222.		0

#	ARTICLE	IF	CITATIONS
37	Title is missing!. , 2020, 17, e1003222.		0
38	Orthogonal analysis of dystrophin protein and mRNA as a surrogate outcome for drug development. Biomarkers in Medicine, 2019, 13, 1209-1225.	1.4	10
39	Pharmacotherapy of Duchenne Muscular Dystrophy. Handbook of Experimental Pharmacology, 2019, 261, 25-37.	1.8	17
40	Disease-specific and glucocorticoid-responsive serum biomarkers for Duchenne Muscular Dystrophy. Scientific Reports, 2019, 9, 12167.	3.3	35
41	Discovery of potential urine-accessible metabolite biomarkers associated with muscle disease and corticosteroid response in the mdx mouse model for Duchenne. PLoS ONE, 2019, 14, e0219507.	2.5	5
42	Influence of β 2 adrenergic receptor genotype on risk of nocturnal ventilation in patients with Duchenne muscular dystrophy. Respiratory Research, 2019, 20, 221.	3.6	8
43	Developmental Pharmacodynamics and Modeling in Pediatric Drug Development. Journal of Clinical Pharmacology, 2019, 59, S87-S94.	2.0	13
44	Biomarkers for Muscle Disease Gene Therapy. , 2019, , 239-252.		0
45	Asymmetric independence modeling identifies novel gene-environment interactions. Scientific Reports, 2019, 9, 2455.	3.3	0
46	Morpholino-induced exon skipping stimulates cell-mediated and humoral responses to dystrophin in mdx mice. Journal of Pathology, 2019, 248, 339-351.	4.5	16
47	Population Pharmacokinetics of Vamorolone (VBP15) in Healthy Men and Boys With Duchenne Muscular Dystrophy. Journal of Clinical Pharmacology, 2019, 59, 979-988.	2.0	11
48	Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function. Neurology, 2019, 93, e1312-e1323.	1.1	64
49	Genome-Wide Association Studies in Muscle Physiology and Disease. , 2019, , 9-30.		2
50	Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy. Life Science Alliance, 2019, 2, e201800186.	2.8	49
51	Congenital Titinopathy: Comprehensive characterization and pathogenic insights. Annals of Neurology, 2018, 83, 1105-1124.	5.3	93
52	A genetic variant in <i>IL15Rα</i> correlates with physical activity among European-American adults. Molecular Genetics & Genomic Medicine, 2018, 6, 401-408.	1.2	10
53	Phase 1 trial of vamorolone, a first-in-class steroid, shows improvements in side effects via biomarkers bridged to clinical outcomes. Steroids, 2018, 134, 43-52.	1.8	54
54	Expression of macrophage genes within skeletal muscle correlates inversely with adiposity and insulin resistance in humans. Applied Physiology, Nutrition and Metabolism, 2018, 43, 187-193.	1.9	7

#	ARTICLE	IF	CITATIONS
55	Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. <i>Lancet, The</i> , 2018, 391, 451-461.	13.7	306
56	PCB exposure and potential future cancer incidence in Slovak children: an assessment from molecular finger printing by Ingenuity Pathway Analysis (IPA®) derived from experimental and epidemiological investigations. <i>Environmental Science and Pollution Research</i> , 2018, 25, 16493-16507.	5.3	24
57	Mechanisms of allelic and clinical heterogeneity of lamin A/C phenotypes. <i>Physiological Genomics</i> , 2018, 50, 694-704.	2.3	8
58	Serum biomarkers of glucocorticoid response and safety in anti-neutrophil cytoplasmic antibody-associated vasculitis and juvenile dermatomyositis. <i>Steroids</i> , 2018, 140, 159-166.	1.8	24
59	Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug. <i>Pharmacological Research</i> , 2018, 136, 140-150.	7.1	69
60	Membrane Stabilization by Modified Steroid Offers a Potential Therapy for Muscular Dystrophy Due to Dysferlin Deficit. <i>Molecular Therapy</i> , 2018, 26, 2231-2242.	8.2	51
61	Muscle miRNAome shows suppression of chronic inflammatory miRNAs with both prednisone and vamorolone. <i>Physiological Genomics</i> , 2018, 50, 735-745.	2.3	30
62	Genetic Variation in Acid Ceramidase Predicts Non-completion of an Exercise Intervention. <i>Frontiers in Physiology</i> , 2018, 9, 781.	2.8	8
63	Neurodevelopmental Needs in Young Boys with Duchenne Muscular Dystrophy (DMD): Observations from the Cooperative International Neuromuscular Research Group (CINRG) DMD Natural History Study (DNHS).. <i>PLOS Currents</i> , 2018, 10, .	1.4	9
64	Evidence for ACTN3 as a genetic modifier of Duchenne muscular dystrophy. <i>Nature Communications</i> , 2017, 8, 14143.	12.8	58
65	Genetic characterization of physical activity behaviours in university students enrolled in kinesiology degree programs. <i>Applied Physiology, Nutrition and Metabolism</i> , 2017, 42, 278-284.	1.9	5
66	miRTarVis+: Web-based interactive visual analytics tool for microRNA target predictions. <i>Methods</i> , 2017, 124, 78-88.	3.8	19
67	Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle. <i>Nature Communications</i> , 2017, 8, 941.	12.8	44
68	The Relationship between Coronary Artery Disease Risk Factors and Carotid Intima-Media Thickness in Children. <i>Journal of Pediatrics</i> , 2017, 190, 38-42.	1.8	12
69	Osteopontin is linked with AKT, FoxO1, and myostatin in skeletal muscle cells. <i>Muscle and Nerve</i> , 2017, 56, 1119-1127.	2.2	12
70	Large meta-analysis of genome-wide association studies identifies five loci for lean body mass. <i>Nature Communications</i> , 2017, 8, 80.	12.8	147
71	The angiotensin-converting enzyme insertion/deletion polymorphism rs4340 associates with habitual physical activity among European American adults. <i>Molecular Genetics & Genomic Medicine</i> , 2017, 5, 524-530.	1.2	7
72	African-American esophageal squamous cell carcinoma expression profile reveals dysregulation of stress response and detox networks. <i>BMC Cancer</i> , 2017, 17, 426.	2.6	18

#	ARTICLE	IF	CITATIONS
73	Novel <i>Col12A1</i> variant expands the clinical picture of congenital myopathies with extracellular matrix defects. <i>Muscle and Nerve</i> , 2017, 55, 277-281.	2.2	31
74	Metataxonomic and Metagenomic Approaches vs. Culture-Based Techniques for Clinical Pathology. <i>Frontiers in Microbiology</i> , 2016, 7, 484.	3.5	78
75	Discovery of Metabolic Biomarkers for Duchenne Muscular Dystrophy within a Natural History Study. <i>PLoS ONE</i> , 2016, 11, e0153461.	2.5	26
76	Targeted Re-Sequencing Emulsion PCR Panel for Myopathies: Results in 94 Cases. <i>Journal of Neuromuscular Diseases</i> , 2016, 3, 209-225.	2.6	18
77	Pyruvate Dehydrogenase Phosphatase Regulatory Gene Expression Correlates with Exercise Training Insulin Sensitivity Changes. <i>Medicine and Science in Sports and Exercise</i> , 2016, 48, 2387-2397.	0.4	7
78	Mathematical modelling of transcriptional heterogeneity identifies novel markers and subpopulations in complex tissues. <i>Scientific Reports</i> , 2016, 6, 18909.	3.3	57
79	Muscle myeloid type I interferon gene expression may predict therapeutic responses to rituximab in myositis patients. <i>Rheumatology</i> , 2016, 55, 1673-1680.	1.9	11
80	Salivary latent trait cortisol (LTC): Relation to lipids, blood pressure, and body composition in middle childhood. <i>Psychoneuroendocrinology</i> , 2016, 71, 110-118.	2.7	9
81	Homozygous mutation in <i>Atlastin GTPase 1</i> causes recessive hereditary spastic paraplegia. <i>Journal of Human Genetics</i> , 2016, 61, 571-573.	2.3	10
82	Examination of Lifestyle Behaviors and Cardiometabolic Risk Factors in University Students Enrolled in Kinesiology Degree Programs. <i>Journal of Strength and Conditioning Research</i> , 2016, 30, 1137-1146.	2.1	6
83	OPN α induces muscle inflammation by increasing recruitment and activation of proinflammatory macrophages. <i>Experimental Physiology</i> , 2016, 101, 1285-1300.	2.0	19
84	Identification of Pathway-Specific Serum Biomarkers of Response to Glucocorticoid and Infliximab Treatment in Children with Inflammatory Bowel Disease. <i>Clinical and Translational Gastroenterology</i> , 2016, 7, e192.	2.5	46
85	<i>DMD</i> genotypes and loss of ambulation in the CINRG Duchenne Natural History Study. <i>Neurology</i> , 2016, 87, 401-409.	1.1	119
86	Association Study of Exon Variants in the NF- κ B and TGF β 2 Pathways Identifies CD40 as a Modifier of Duchenne Muscular Dystrophy. <i>American Journal of Human Genetics</i> , 2016, 99, 1163-1171.	6.2	71
87	Serum pharmacodynamic biomarkers for chronic corticosteroid treatment of children. <i>Scientific Reports</i> , 2016, 6, 31727.	3.3	40
88	Laminopathies disrupt epigenomic developmental programs and cell fate. <i>Science Translational Medicine</i> , 2016, 8, 335ra58.	12.4	91
89	Clinical utility of serum biomarkers in Duchenne muscular dystrophy. <i>Clinical Proteomics</i> , 2016, 13, 9.	2.1	70
90	Diagnosis and etiology of congenital muscular dystrophy: We are halfway there. <i>Annals of Neurology</i> , 2016, 80, 101-111.	5.3	57

#	ARTICLE	IF	CITATIONS
91	Somatic mosaicism due to a reversion variant causing hemi-atrophy: a novel variant of dystrophinopathy. <i>European Journal of Human Genetics</i> , 2016, 24, 1511-1514.	2.8	8
92	Glucocorticoid Receptor (NR3C1) Variants Associate with the Muscle Strength and Size Response to Resistance Training. <i>PLoS ONE</i> , 2016, 11, e0148112.	2.5	9
93	miRTarVis: an interactive visual analysis tool for microRNA-mRNA expression profile data. <i>BMC Proceedings</i> , 2015, 9, S2.	1.6	64
94	TNF- α -Induced microRNAs Control Dystrophin Expression in Becker Muscular Dystrophy. <i>Cell Reports</i> , 2015, 12, 1678-1690.	6.4	62
95	Elusive sources of variability of dystrophin rescue by exon skipping. <i>Skeletal Muscle</i> , 2015, 5, 44.	4.2	26
96	The ACTN3 R577X Polymorphism Is Associated with Cardiometabolic Fitness in Healthy Young Adults. <i>PLoS ONE</i> , 2015, 10, e0130644.	2.5	30
97	Genetic modifiers of ambulation in the cooperative international Neuromuscular research group Duchenne natural history study. <i>Annals of Neurology</i> , 2015, 77, 684-696.	5.3	111
98	Upregulated IL-1 β in dysferlin-deficient muscle attenuates regeneration by blunting the response to pro-inflammatory macrophages. <i>Skeletal Muscle</i> , 2015, 5, 24.	4.2	26
99	Exome Sequencing Identifies DYNC1H1 Variant Associated With Vertebral Abnormality and Spinal Muscular Atrophy With Lower Extremity Predominance. <i>Pediatric Neurology</i> , 2015, 52, 239-244.	2.1	27
100	VBP15, a Novel Anti-Inflammatory, is Effective at Reducing the Severity of Murine Experimental Autoimmune Encephalomyelitis. <i>Cellular and Molecular Neurobiology</i> , 2015, 35, 377-387.	3.3	21
101	Recessive ACTA1 variant causes congenital muscular dystrophy with rigid spine. <i>European Journal of Human Genetics</i> , 2015, 23, 883-886.	2.8	23
102	An analysis of DNA methylation in human adipose tissue reveals differential modification of obesity genes before and after gastric bypass and weight loss. <i>Genome Biology</i> , 2015, 16, 8.	8.8	200
103	Immune-mediated pathology in Duchenne muscular dystrophy. <i>Science Translational Medicine</i> , 2015, 7, 299rv4.	12.4	209
104	Dystrophinopathies. , 2015, , 1103-1111.		2
105	Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 7153-7158.	7.1	235
106	Transcriptional profiling and biological pathway analysis of human equivalence PCB exposure in vitro: Indicator of disease and disorder development in humans. <i>Environmental Research</i> , 2015, 138, 202-216.	7.5	19
107	Contemporary Cardiac Issues in Duchenne Muscular Dystrophy. <i>Circulation</i> , 2015, 131, 1590-1598.	1.6	240
108	Obesity-Related Genetic Variants and their Associations with Physical Activity. <i>Sports Medicine - Open</i> , 2015, 1, 34.	3.1	15

#	ARTICLE	IF	CITATIONS
109	Global Gene Expression Profiling in R155H Knock-In Murine Model of VCP Disease. Clinical and Translational Science, 2015, 8, 8-16.	3.1	3
110	Prednisone/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study. Neurology, 2015, 85, 1048-1055.	1.1	138
111	The use of urinary and kidney SILAM proteomics to monitor kidney response to high dose morpholino oligonucleotides in the mdx mouse. Toxicology Reports, 2015, 2, 838-849.	3.3	24
112	KDDN: an open-source Cytoscape app for constructing differential dependency networks with significant rewiring. Bioinformatics, 2015, 31, 287-289.	4.1	17
113	Genetic Modifiers of Duchenne Muscular Dystrophy and Dilated Cardiomyopathy. PLoS ONE, 2015, 10, e0141240.	2.5	58
114	Discovery of serum protein biomarkers in the mdx mouse model and cross-species comparison to Duchenne muscular dystrophy patients. Human Molecular Genetics, 2014, 23, 6458-6469.	2.9	106
115	Natural Progression of Childhood Asthma Symptoms and Strong Influence of Sex and Puberty. Annals of the American Thoracic Society, 2014, 11, 939-944.	3.2	75
116	Pharmacologic Management of Duchenne Muscular Dystrophy: Target Identification and Preclinical Trials. ILAR Journal, 2014, 55, 119-149.	1.8	44
117	Mitotic Asynchrony Induces Transforming Growth Factor- β 1 Secretion from Airway Epithelium. American Journal of Respiratory Cell and Molecular Biology, 2014, 51, 363-369.	2.9	12
118	Response to Comment on Sprouse et al.SLC30A8Nonsynonymous Variant Is Associated With Recovery Following Exercise and Skeletal Muscle Size and Strength. Diabetes 2014;63:363-368. Diabetes, 2014, 63, e9-e10.	0.6	3
119	Eccentric muscle challenge shows osteopontin polymorphism modulation of muscle damage. Human Molecular Genetics, 2014, 23, 4043-4050.	2.9	22
120	Exon-Skipping Therapy: A Roadblock, Detour, or Bump in the Road?. Science Translational Medicine, 2014, 6, 230fs14.	12.4	32
121	Rhinovirus infection in young children is associated with elevated airway TSLP levels. European Respiratory Journal, 2014, 44, 1075-1078.	6.7	45
122	Neck and Waist Circumference Biomarkers of Cardiovascular Risk in a Cohort of Predominantly African-American College Students: A Preliminary Study. Journal of the Academy of Nutrition and Dietetics, 2014, 114, 107-116.	0.8	27
123	SLC30A8 Nonsynonymous Variant Is Associated With Recovery Following Exercise and Skeletal Muscle Size and Strength. Diabetes, 2014, 63, 363-368.	0.6	20
124	Multi-omic integrated networks connect DNA methylation and miRNA with skeletal muscle plasticity to chronic exercise in Type 2 diabetic obesity. Physiological Genomics, 2014, 46, 747-765.	2.3	100
125	Single-Molecule Long-Read 16S Sequencing To Characterize the Lung Microbiome from Mechanically Ventilated Patients with Suspected Pneumonia. Journal of Clinical Microbiology, 2014, 52, 3913-3921.	3.9	69
126	A rebirth for drisapersen in Duchenne muscular dystrophy?. Lancet Neurology, The, 2014, 13, 963-965.	10.2	5

#	ARTICLE	IF	CITATIONS
127	Metabolite signatures of exercise training in human skeletal muscle relate to mitochondrial remodelling and cardiometabolic fitness. <i>Diabetologia</i> , 2014, 57, 2282-2295.	6.3	121
128	Asynchronous remodeling is a driver of failed regeneration in Duchenne muscular dystrophy. <i>Journal of Cell Biology</i> , 2014, 207, 139-158.	5.2	130
129	Knowledge-fused differential dependency network models for detecting significant rewiring in biological networks. <i>BMC Systems Biology</i> , 2014, 8, 87.	3.0	26
130	Predicting age at loss of ambulation in Duchenne muscular dystrophy with deep phenotypic measures. , 2014, , .		0
131	Non-Invasive MRI and Spectroscopy of mdx Mice Reveal Temporal Changes in Dystrophic Muscle Imaging and in Energy Deficits. <i>PLoS ONE</i> , 2014, 9, e112477.	2.5	26
132	Molecular Diagnosis and Genetic Testing. , 2014, , 271-284.		0
133	ACTN3 genotype predicts metabolic, anthropometric and cardiovascular phenotypes in a young, healthy population (711.8). <i>FASEB Journal</i> , 2014, 28, 711.8.	0.5	0
134	The SORT1 risk allele is associated with exaggerated postprandial lipaemia in young adults (383.5). <i>FASEB Journal</i> , 2014, 28, 383.5.	0.5	0
135	A novel mutation expands the genetic and clinical spectrum of MYH7-related myopathies. <i>Neuromuscular Disorders</i> , 2013, 23, 432-436.	0.6	35
136	Microarray Analysis Reveals Novel Features of the Muscle Aging Process in Men and Women. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2013, 68, 1035-1044.	3.6	50
137	Mutations in GDP-Mannose Pyrophosphorylase B Cause Congenital and Limb-Girdle Muscular Dystrophies Associated with Hypoglycosylation of α -Dystroglycan. <i>American Journal of Human Genetics</i> , 2013, 93, 29-41.	6.2	197
138	Sparing of the Dystrophin-Deficient Cranial Sartorius Muscle Is Associated with Classical and Novel Hypertrophy Pathways in GRMD Dogs. <i>American Journal of Pathology</i> , 2013, 183, 1411-1424.	3.8	37
139	Impaired autophagy, chaperone expression, and protein synthesis in response to critical illness interventions in porcine skeletal muscle. <i>Physiological Genomics</i> , 2013, 45, 477-486.	2.3	27
140	Effect of the SORT1 low-density lipoprotein cholesterol locus is sex-specific in a fit, Canadian young-adult population. <i>Applied Physiology, Nutrition and Metabolism</i> , 2013, 38, 188-193.	1.9	9
141	VBP15: Preclinical characterization of a novel anti-inflammatory delta 9,11 steroid. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 2241-2249.	3.0	50
142	Effects of corticosteroids in the development of limb muscle weakness in a porcine intensive care unit model. <i>Physiological Genomics</i> , 2013, 45, 312-320.	2.3	15
143	Alterations in Osteopontin Modify Muscle Size in Females in Both Humans and Mice. <i>Medicine and Science in Sports and Exercise</i> , 2013, 45, 1060-1068.	0.4	35
144	Highlights from the Functional Single Nucleotide Polymorphisms Associated with Human Muscle Size and Strength or FAMuSS Study. <i>BioMed Research International</i> , 2013, 2013, 1-11.	1.9	22

#	ARTICLE	IF	CITATIONS
145	Identification of Disease Specific Pathways Using in Vivo SILAC Proteomics in Dystrophin Deficient mdx Mouse. <i>Molecular and Cellular Proteomics</i> , 2013, 12, 1061-1073.	3.8	88
146	Short Read (Next-Generation) Sequencing. <i>Circulation: Cardiovascular Genetics</i> , 2013, 6, 427-434.	5.1	23
147	The cooperative international neuromuscular research group duchenne natural history studyâ€”a longitudinal investigation in the era of glucocorticoid therapy: Design of protocol and the methods used. <i>Muscle and Nerve</i> , 2013, 48, 32-54.	2.2	145
148	Differential Gene Expression Reveals Mitochondrial Dysfunction in an Imprinting Center Deletion Mouse Model of Praderâ€™Willi Syndrome. <i>Clinical and Translational Science</i> , 2013, 6, 347-355.	3.1	23
149	The cooperative international neuromuscular research group Duchenne natural history study: Glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measures. <i>Muscle and Nerve</i> . 2013. 48. 55-67.	2.2	164
150	The effects of MyD88 deficiency on disease phenotype in dysferlin-deficient A/J mice: role of endogenous TLR ligands. <i>Journal of Pathology</i> , 2013, 231, 199-209.	4.5	22
151	VBP15, a novel antiâ€™inflammatory and membraneâ€™stabilizer, improves muscular dystrophy without side effects. <i>EMBO Molecular Medicine</i> , 2013, 5, 1569-1585.	6.9	148
152	Moderate-Intensity Aerobic Training Program Improves Insulin Sensitivity and Inflammatory Markers in a Pilot Study of Morbidly Obese Minority Teens. <i>Pediatric Exercise Science</i> , 2013, 25, 12-26.	1.0	28
153	Status of LEPR Gene in PCB-exposed Population: A Quick Look. <i>International Journal of Human Genetics</i> , 2013, 13, 27-32.	0.1	10
154	VBP15, a Glucocorticoid Analogue, Is Effective at Reducing Allergic Lung Inflammation in Mice. <i>PLoS ONE</i> , 2013, 8, e63871.	2.5	24
155	The Proton Pump Inhibitor Lansoprazole Improves the Skeletal Phenotype in Dystrophin Deficient mdx Mice. <i>PLoS ONE</i> , 2013, 8, e66617.	2.5	3
156	Aging influences the expression of early response genes following acute resistance exercise in trained skeletal muscle. <i>FASEB Journal</i> , 2013, 27, 710.3.	0.5	0
157	Asymptomatic African Americans with highâ€™risk APOL1 genotypes have reduced urinary angiogenesisâ€™promoting cytokines. <i>FASEB Journal</i> , 2013, 27, 1b474.	0.5	0
158	Orphan drug development in muscular dystrophy: update on two large clinical trials of dystrophin rescue therapies. <i>Discovery Medicine</i> , 2013, 16, 233-9.	0.5	48
159	Endothelial Nitric Oxide Synthase (NOS3) +894â€™G>T Associates with Physical Activity and Muscle Performance among Young Adults. <i>ISRN Vascular Medicine</i> , 2012, 2012, 1-7.	0.7	4
160	Bodywide skipping of exons 45â€™55 in dystrophic mdx52 mice by systemic antisense delivery. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 13763-13768.	7.1	139
161	Î³-9,11 Modification of Glucocorticoids Dissociates Nuclear Factor-Î² Inhibitory Efficacy from Glucocorticoid Response Element-Associated Side Effects. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2012, 343, 225-232.	2.5	27
162	Understanding the molecular complexity of medulloblastoma. <i>Nature Reviews Neurology</i> , 2012, 8, 539-540.	10.1	6

#	ARTICLE	IF	CITATIONS
163	Mexiletine for Treatment of Myotonia. JAMA - Journal of the American Medical Association, 2012, 308, 1377.	7.4	17
164	Resistance exercise training influences skeletal muscle immune activation: a microarray analysis. Journal of Applied Physiology, 2012, 112, 443-453.	2.5	79
165	Importance of <i>SPP1</i> genotype as a covariate in clinical trials in Duchenne muscular dystrophy. Neurology, 2012, 79, 159-162.	1.1	81
166	Microtubules Underlie Dysfunction in Duchenne Muscular Dystrophy. Science Signaling, 2012, 5, ra56.	3.6	222
167	Variants of the Ankyrin Repeat Domain 6 Gene (ANKRD6) and Muscle and Physical Activity Phenotypes Among European-Derived American Adults. Journal of Strength and Conditioning Research, 2012, 26, 1740-1748.	2.1	20
168	Role of sepsis in the development of limb muscle weakness in a porcine intensive care unit model. Physiological Genomics, 2012, 44, 865-877.	2.3	16
169	Sphingosine-1-Phosphate Enhances Satellite Cell Activation in Dystrophic Muscles through a S1PR2/STAT3 Signaling Pathway. PLoS ONE, 2012, 7, e37218.	2.5	64
170	<i>TGFBR2</i> but not <i>SPP1</i> genotype modulates osteopontin expression in Duchenne muscular dystrophy muscle. Journal of Pathology, 2012, 228, 251-259.	4.5	22
171	Novel Approaches to Corticosteroid Treatment in Duchenne Muscular Dystrophy. Physical Medicine and Rehabilitation Clinics of North America, 2012, 23, 821-828.	1.3	48
172	Differential gene expression and a functional analysis of PCB-exposed children: Understanding disease and disorder development. Environment International, 2012, 40, 143-154.	10.0	42
173	Analysis of the toxicogenomic effects of exposure to persistent organic pollutants (POPs) in Slovakian girls: Correlations between gene expression and disease risk. Environment International, 2012, 39, 188-199.	10.0	42
174	Genome-wide identification of significant aberrations in cancer genome. BMC Genomics, 2012, 13, 342.	2.8	34
175	Metabolic remodeling agents show beneficial effects in the dystrophin- deficient mdx mouse model. Skeletal Muscle, 2012, 2, 16.	4.2	74
176	Eps homology domain endosomal transport proteins differentially localize to the neuromuscular junction. Skeletal Muscle, 2012, 2, 19.	4.2	10
177	Genomics, Intellectual Disability, and Autism. New England Journal of Medicine, 2012, 366, 733-743.	27.0	276
178	The Paradox of Muscle Hypertrophy in Muscular Dystrophy. Physical Medicine and Rehabilitation Clinics of North America, 2012, 23, 149-172.	1.3	85
179	Glucocorticoid-Treated Mice Are an Inappropriate Positive Control for Long-Term Preclinical Studies in the mdx Mouse. PLoS ONE, 2012, 7, e34204.	2.5	55
180	Extensive and Prolonged Restoration of Dystrophin Expression with Vivo-Morpholino-Mediated Multiple Exon Skipping in Dystrophic Dogs. Nucleic Acid Therapeutics, 2012, 22, 306-315.	3.6	69

#	ARTICLE	IF	CITATIONS
181	A calm before the exome storm. <i>Neurology</i> , 2012, 78, 1706-1707.	1.1	6
182	Deletion of galectin-3 exacerbates microglial activation and accelerates disease progression and demise in a <scp>SOD1</scp>^{G93A} mouse model of amyotrophic lateral sclerosis. <i>Brain and Behavior</i> , 2012, 2, 563-575.	2.2	76
183	Characterization of transferrin glycopeptide structures in human cerebrospinal fluid. <i>International Journal of Mass Spectrometry</i> , 2012, 312, 97-106.	1.5	19
184	Global Gene Profiling of VCP-associated Inclusion Body Myopathy. <i>Clinical and Translational Science</i> , 2012, 5, 226-234.	3.1	10
185	Computational analysis of muscular dystrophy sub-types using a novel integrative scheme. <i>Neurocomputing</i> , 2012, 92, 9-17.	5.9	3
186	Canine models of Duchenne muscular dystrophy and their use in therapeutic strategies. <i>Mammalian Genome</i> , 2012, 23, 85-108.	2.2	140
187	Accurate Quantitation of Dystrophin Protein in Human Skeletal Muscle Using Mass Spectrometry. <i>Journal of Bioanalysis & Biomedicine</i> , 2012, s7, .	0.1	32
188	Evolution and comparative genomics of subcellular specializations: EST sequencing of Torpedo electric organ. <i>Marine Genomics</i> , 2011, 4, 33-40.	1.1	6
189	Proteomic responses of skeletal and cardiac muscle to exercise. <i>Expert Review of Proteomics</i> , 2011, 8, 361-377.	3.0	62
190	Antisense Oligo-Mediated Multiple Exon Skipping in a Dog Model of Duchenne Muscular Dystrophy. <i>Methods in Molecular Biology</i> , 2011, 709, 299-312.	0.9	39
191	Restoring Dystrophin Expression in Duchenne Muscular Dystrophy Muscle. <i>American Journal of Pathology</i> , 2011, 179, 12-22.	3.8	89
192	Global gene expression and Ingenuity biological functions analysis on PCBs 153 and 138 induced human PBMC in vitro reveals differential mode(s) of action in developing toxicities. <i>Environment International</i> , 2011, 37, 838-857.	10.0	32
193	<i>MC4R</i> Variant Is Associated With BMI but Not Response to Resistance Training in Young Females. <i>Obesity</i> , 2011, 19, 662-666.	3.0	17
194	Non-invasive Optical Imaging of Muscle Pathology in mdx Mice Using Cathepsin Caged Near-Infrared Imaging. <i>Molecular Imaging and Biology</i> , 2011, 13, 462-470.	2.6	27
195	Progression of volume load and muscular adaptation during resistance exercise. <i>European Journal of Applied Physiology</i> , 2011, 111, 1063-1071.	2.5	54
196	AKT1 polymorphisms are associated with risk for metabolic syndrome. <i>Human Genetics</i> , 2011, 129, 129-139.	3.8	29
197	Characterization of the ZBTB42 gene in humans and mice. <i>Human Genetics</i> , 2011, 129, 433-441.	3.8	5
198	Membrane Sealant Poloxamer P188 Protects Against Isoproterenol Induced Cardiomyopathy in Dystrophin Deficient Mice. <i>BMC Cardiovascular Disorders</i> , 2011, 11, 20.	1.7	64

#	ARTICLE	IF	CITATIONS
199	Delayed inflammatory mRNA and protein expression after spinal cord injury. Journal of Neuroinflammation, 2011, 8, 130.	7.2	66
200	Integrated genomics and proteomics of the Torpedo californica electric organ: concordance with the mammalian neuromuscular junction. Skeletal Muscle, 2011, 1, 20.	4.2	14
201	Motif-guided sparse decomposition of gene expression data for regulatory module identification. BMC Bioinformatics, 2011, 12, 82.	2.6	13
202	Transcriptional deficits in oxidative phosphorylation with statin myopathy. Muscle and Nerve, 2011, 44, 393-401.	2.2	31
203	DDN: a caBIGA [®] analytical tool for differential network analysis. Bioinformatics, 2011, 27, 1036-1038.	4.1	39
204	Asthmatic Airway Epithelium Is Intrinsically Inflammatory and Mitotically Dyssynchronous. American Journal of Respiratory Cell and Molecular Biology, 2011, 44, 863-869.	2.9	69
205	The 1p13.3 LDL (C)-Associated Locus Shows Large Effect Sizes in Young Populations. Pediatric Research, 2011, 69, 538-543.	2.3	15
206	Losartan Decreases Cardiac Muscle Fibrosis and Improves Cardiac Function in Dystrophin-Deficient Mdx Mice. Journal of Cardiovascular Pharmacology and Therapeutics, 2011, 16, 87-95.	2.0	90
207	PUGSVM: a caBIGTM analytical tool for multiclass gene selection and predictive classification. Bioinformatics, 2011, 27, 736-738.	4.1	19
208	Mechanisms underlying the sparing of masticatory versus limb muscle function in an experimental critical illness model. Physiological Genomics, 2011, 43, 1334-1350.	2.3	30
209	<i>CCL2</i> and <i>CCR2</i> variants are associated with skeletal muscle strength and change in strength with resistance training. Journal of Applied Physiology, 2010, 109, 1779-1785.	2.5	34
210	A Longitudinal, Integrated, Clinical, Histological and mRNA Profiling Study of Resistance Exercise in Myositis. Molecular Medicine, 2010, 16, 455-464.	4.4	74
211	A polymorphism near IGF1 is associated with body composition and muscle function in women from the Health, Aging, and Body Composition Study. European Journal of Applied Physiology, 2010, 110, 315-324.	2.5	25
212	Functional characterization of a haplotype in the AKT1 gene associated with glucose homeostasis and metabolic syndrome. Human Genetics, 2010, 128, 635-645.	3.8	11
213	Limbs "Girdle and Congenital Muscular Dystrophies: Current Diagnostics, Management, and Emerging Technologies. Current Neurology and Neuroscience Reports, 2010, 10, 267-276.	4.2	46
214	Knowledge-guided gene ranking by coordinative component analysis. BMC Bioinformatics, 2010, 11, 162.	2.6	8
215	Skeletal muscle gene expression in response to resistance exercise: sex specific regulation. BMC Genomics, 2010, 11, 659.	2.8	91
216	Asthmatic Bronchial Epithelium Is Intrinsically Inflammogenic, Mitotically Dyssynchronous, And Is Rescued By Glucocorticoids. , 2010, , .		2

#	ARTICLE	IF	CITATIONS
217	Glucocorticoid Efficacy in Asthma is Improved Tissue Remodeling Upstream of Anti-Inflammation. Journal of Investigative Medicine, 2010, 58, 19-22.	1.6	23
218	Evaluation of Skeletal and Cardiac Muscle Function after Chronic Administration of Thymosin β 4 in the Dystrophin Deficient Mouse. PLoS ONE, 2010, 5, e8976.	2.5	19
219	Functional and Molecular Effects of Arginine Butyrate and Prednisone on Muscle and Heart in the mdx Mouse Model of Duchenne Muscular Dystrophy. PLoS ONE, 2010, 5, e11220.	2.5	37
220	Computational Analysis of Muscular Dystrophy Sub-types Using a Novel Integrative Scheme. , 2010, , .		0
221	<i>CCL2</i> and <i>CCR2</i> polymorphisms are associated with markers of exercise-induced skeletal muscle damage. Journal of Applied Physiology, 2010, 108, 1651-1658.	2.5	57
222	Forty-eight hours of unloading and 24 h of reloading lead to changes in global gene expression patterns related to ubiquitination and oxidative stress in humans. Journal of Applied Physiology, 2010, 109, 1404-1415.	2.5	74
223	PCB congener specific oxidative stress response by microarray analysis using human liver cell line. Environment International, 2010, 36, 907-917.	10.0	40
224	Inflammasome Up-Regulation and Activation in Dysferlin-Deficient Skeletal Muscle. American Journal of Pathology, 2010, 176, 2891-2900.	3.8	144
225	Characterization of Dysferlin Deficient SJL/J Mice to Assess Preclinical Drug Efficacy: Fasudil Exacerbates Muscle Disease Phenotype. PLoS ONE, 2010, 5, e12981.	2.5	31
226	Strength, Size, and Muscle Quality in the Upper Arm following Unilateral Training in Younger and Older Males and Females. Clinical Medicine: Arthritis and Musculoskeletal Disorders, 2009, 2, CMAMD.S1180.	0.0	5
227	MHC Class II Deficiency. , 2009, , 1306-1308.		0
228	Osteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF- β 2. Journal of Clinical Investigation, 2009, 119, 1583-1594.	8.2	251
229	A Renaissance for Antisense Oligonucleotide Drugs in Neurology. Archives of Neurology, 2009, 66, 32-8.	4.5	58
230	Gene expression and muscle fiber function in a porcine ICU model. Physiological Genomics, 2009, 39, 141-159.	2.3	45
231	Differential dependency network analysis to identify condition-specific topological changes in biological networks. Bioinformatics, 2009, 25, 526-532.	4.1	127
232	CNTF 1357 G \rightarrow A polymorphism and the muscle strength response to resistance training. Journal of Applied Physiology, 2009, 107, 1235-1240.	2.5	24
233	Somatic mosaicism for Duchenne dystrophy: Evidence for genetic normalization mitigating muscle symptoms. American Journal of Medical Genetics, Part A, 2009, 149A, 1499-1503.	1.2	18
234	Efficacy of systemic morpholino exon-skipping in duchenne dystrophy dogs. Annals of Neurology, 2009, 65, 667-676.	5.3	356

#	ARTICLE	IF	CITATIONS
235	Differences in fat and muscle mass associated with a functional human polymorphism in a post-transcriptional <i>BMP2</i> gene regulatory element. <i>Journal of Cellular Biochemistry</i> , 2009, 107, 1073-1082.	2.6	34
236	Preclinical drug trials in the <i>mdx</i> mouse: Assessment of reliable and sensitive outcome measures. <i>Muscle and Nerve</i> , 2009, 39, 591-602.	2.2	137
237	In vitro analysis of metabolites from the untreated tissue of <i>Torpedo californica</i> electric organ by mid-infrared laser ablation electrospray ionization mass spectrometry. <i>Metabolomics</i> , 2009, 5, 263-276.	3.0	42
238	A robust in vitro screening assay to identify NF- κ B inhibitors for inflammatory muscle diseases. <i>International Immunopharmacology</i> , 2009, 9, 1209-1214.	3.8	30
239	Proteomic profiling of glucocorticoid-exposed myogenic cells: Time series assessment of protein translocation and transcription of inactive mRNAs. <i>Proteome Science</i> , 2009, 7, 26.	1.7	8
240	GeneShelf: A Web-based Visual Interface for Large Gene Expression Time-Series Data Repositories. <i>IEEE Transactions on Visualization and Computer Graphics</i> , 2009, 15, 905-912.	4.4	12
241	Investigation of gene Expression in C2C12 Myotubes Following simvastatin Application and Mechanical Strain. <i>Journal of Atherosclerosis and Thrombosis</i> , 2009, 16, 21-29.	2.0	20
242	Association of Age with Muscle Size and Strength Before and After Short-Term Resistance Training in Young Adults. <i>Journal of Strength and Conditioning Research</i> , 2009, 23, 1915-1920.	2.1	13
243	Delineation of a Gene Network Underlying the Pulmonary Response to Oxidative Stress in Asthma. <i>Journal of Investigative Medicine</i> , 2009, 57, 756-764.	1.6	15
244	Myostatin and Follistatin Polymorphisms Interact with Muscle Phenotypes and Ethnicity. <i>Medicine and Science in Sports and Exercise</i> , 2009, 41, 1063-1071.	0.4	46
245	PCB Exposure In Vitro (PBMC): Differential Gene Expression, Pathway Analysis for Possible Mode(s) of Actions, and Disease Development in Comparison with PCB-Exposed Slovak Population. <i>Epidemiology</i> , 2009, 20, S130.	2.7	2
246	Identification of Early Disease Biomarkers in 45 Months PCB-Exposed Slovak Population. <i>Epidemiology</i> , 2009, 20, S131.	2.7	1
247	The Genomic Basis of Neuromuscular Disorders. , 2009, , 1265-1281.		0
248	INSIG2 gene polymorphism is associated with increased subcutaneous fat in women and poor response to resistance training in men. <i>BMC Medical Genetics</i> , 2008, 9, 117.	2.1	22
249	Integrated DNA, cDNA, and protein studies in Becker muscular dystrophy show high exception to the reading frame rule. <i>Human Mutation</i> , 2008, 29, 728-737.	2.5	75
250	caBIG, VISDA: Modeling, visualization, and discovery for cluster analysis of genomic data. <i>BMC Bioinformatics</i> , 2008, 9, 383.	2.6	12
251	Knowledge-guided multi-scale independent component analysis for biomarker identification. <i>BMC Bioinformatics</i> , 2008, 9, 416.	2.6	23
252	Motif-directed network component analysis for regulatory network inference. <i>BMC Bioinformatics</i> , 2008, 9, S21.	2.6	22

#	ARTICLE	IF	CITATIONS
253	Time Series Proteome Profiling To Study Endoplasmic Reticulum Stress Response. Journal of Proteome Research, 2008, 7, 2435-2444.	3.7	35
254	Dystrophin-deficient cardiomyopathy in mouse: Expression of Nox4 and Lox are associated with fibrosis and altered functional parameters in the heart. Neuromuscular Disorders, 2008, 18, 371-381.	0.6	127
255	CYP1A1 and MT1K are congener specific biomarker genes for liver diseases induced by PCBs. Environmental Toxicology and Pharmacology, 2008, 25, 218-221.	4.0	16
256	Interleukin-15 and interleukin-15R α SNPs and associations with muscle, bone, and predictors of the metabolic syndrome. Cytokine, 2008, 43, 45-53.	3.2	63
257	Glucose Restriction Inhibits Skeletal Myoblast Differentiation by Activating SIRT1 through AMPK-Mediated Regulation of Nampt. Developmental Cell, 2008, 14, 661-673.	7.0	701
258	Dysferlin Deficiency Enhances Monocyte Phagocytosis. American Journal of Pathology, 2008, 172, 774-785.	3.8	115
259	Dysferlin Deficiency Shows Compensatory Induction of Rab27A/Slp2a That May Contribute to Inflammatory Onset. American Journal of Pathology, 2008, 173, 1476-1487.	3.8	38
260	Mathematical Modeling of Corticosteroid Pharmacogenomics in Rat Muscle following Acute and Chronic Methylprednisolone Dosing. Molecular Pharmaceutics, 2008, 5, 328-339.	4.6	24
261	Relationships between circadian rhythms and modulation of gene expression by glucocorticoids in skeletal muscle. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2008, 295, R1031-R1047.	1.8	64
262	Transcriptional Cascades in Muscle Regeneration. , 2008, , 85-106.		2
263	Microarray analysis of the temporal response of skeletal muscle to methylprednisolone: comparative analysis of two dosing regimens. Physiological Genomics, 2007, 30, 282-299.	2.3	54
264	Proteomics and Systems Biology in Exercise and Sport Sciences Research. Exercise and Sport Sciences Reviews, 2007, 35, 5-11.	3.0	22
265	Skippping toward Personalized Molecular Medicine. New England Journal of Medicine, 2007, 357, 2719-2722.	27.0	60
266	Gene Selection for Multiclass Prediction by Weighted Fisher Criterion. Eurasip Journal on Bioinformatics and Systems Biology, 2007, 2007, 1-15.	1.4	10
267	IGF-II gene region polymorphisms related to exertional muscle damage. Journal of Applied Physiology, 2007, 102, 1815-1823.	2.5	52
268	Subcutaneous Fat Alterations Resulting from an Upper-Body Resistance Training Program. Medicine and Science in Sports and Exercise, 2007, 39, 1177-1185.	0.4	24
269	Allometric Scaling of Biceps Strength before and after Resistance Training in Men. Medicine and Science in Sports and Exercise, 2007, 39, 1013-1019.	0.4	12
270	Biomarker Identification by Knowledge-Driven Multi-Level ICA and Motif Analysis. , 2007, , .		5

#	ARTICLE	IF	CITATIONS
271	PPARÎ± L162V underlies variation in serum triglycerides and subcutaneous fat volume in young males. BMC Medical Genetics, 2007, 8, 55.	2.1	37
272	The proteome survey of an electricity-generating organ(Torpedo californicaelectric organ). Proteomics, 2007, 7, 617-627.	2.2	19
273	Resistin Polymorphisms Are Associated with Muscle, Bone, and Fat Phenotypes in White Men and Women. Obesity, 2007, 15, 392-402.	3.0	29
274	AKT1 Association with Body Composition. Medicine and Science in Sports and Exercise, 2007, 39, S14.	0.4	1
275	The Muscle Strength and Size Response to Upper Arm, Unilateral Resistance Training Among Adults Who Are Overweight and Obese. Journal of Strength and Conditioning Research, 2007, 21, 307.	2.1	31
276	Platelet Granzyme B expression is increased in sepsis: a potential mechanism for sepsis-associated endothelial apoptosis. FASEB Journal, 2007, 21, A1125.	0.5	1
277	Elucidating the Role of SNPs in AKT1 Gene Expression. FASEB Journal, 2007, 21, A1152.	0.5	0
278	Composite Gene Module Discovery using Non-negative Independent Component Analysis. , 2006, , .		0
279	Translating Mighty Mice into Neuromuscular Therapeutics. American Journal of Pathology, 2006, 168, 1775-1778.	3.8	9
280	ACE ID Genotype and the Muscle Strength and Size Response to Unilateral Resistance Training. Medicine and Science in Sports and Exercise, 2006, 38, 1074-1081.	0.4	89
281	GRB14, GPD1, and GDF8 as potential network collaborators in weight loss-induced improvements in insulin action in human skeletal muscle. Physiological Genomics, 2006, 27, 114-121.	2.3	129
282	Functional recovery of glycine receptors in spastic murine model of startle disease. Neurobiology of Disease, 2006, 21, 291-304.	4.4	16
283	Probe set algorithms: is there a rational best bet?. BMC Bioinformatics, 2006, 7, 395.	2.6	75
284	Sexual dimorphism in immune response genes as a function of puberty. BMC Immunology, 2006, 7, 2.	2.2	104
285	Expression of two temporally distinct microglia-related gene clusters after spinal cord injury. Glia, 2006, 53, 420-433.	4.9	72
286	Automated sequence screening of the entire dystrophin cdna in Duchenne dystrophy: Point mutation detection. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2006, 141B, 44-50.	1.7	22
287	Fgfr4 Is Required for Effective Muscle Regeneration in Vivo. Journal of Biological Chemistry, 2006, 281, 429-438.	3.4	90
288	Nuclear envelope dystrophies show a transcriptional fingerprint suggesting disruption of Rb-MyoD pathways in muscle regeneration. Brain, 2006, 129, 996-1013.	7.6	288

#	ARTICLE	IF	CITATIONS
289	An interactive power analysis tool for microarray hypothesis testing and generation. <i>Bioinformatics</i> , 2006, 22, 808-814.	4.1	133
290	Loss of emerin at the nuclear envelope disrupts the Rb1/E2F and MyoD pathways during muscle regeneration. <i>Human Molecular Genetics</i> , 2006, 15, 637-651.	2.9	197
291	Endothelial cell activation and neovascularization are prominent in dermatomyositis. <i>Journal of Autoimmune Diseases</i> , 2006, 3, 2.	1.0	69
292	Skeletal muscle remodeling during hypertrophy involves the coordinated expression of growth and atrophy genes. <i>FASEB Journal</i> , 2006, 20, A392.	0.5	0
293	Muscular Dystrophies. , 2006, , 1080-1087.		0
294	Phenotypic-Specific Gene Module Discovery using a Diagnostic Tree and caBIGTM VISDA. Annual International Conference of the IEEE Engineering in Medicine and Biology Society, 2006, , .	0.5	0
295	Latent Variable and nICA Modeling of Pathway Gene Module Composite. Annual International Conference of the IEEE Engineering in Medicine and Biology Society, 2006, , .	0.5	0
296	Definition of the unique human extraocular muscle allotype by expression profiling. <i>Physiological Genomics</i> , 2005, 22, 283-291.	2.3	76
297	Intracellular expression profiling by laser capture microdissection: three novel components of the neuromuscular junction. <i>Physiological Genomics</i> , 2005, 21, 70-80.	2.3	38
298	ACTN3 and MLCK genotype associations with exertional muscle damage. <i>Journal of Applied Physiology</i> , 2005, 99, 564-569.	2.5	171
299	Multiple-laboratory comparison of microarray platforms. <i>Nature Methods</i> , 2005, 2, 345-350.	19.0	814
300	Activation of the endoplasmic reticulum stress response in autoimmune myositis: Potential role in muscle fiber damage and dysfunction. <i>Arthritis and Rheumatism</i> , 2005, 52, 1824-1835.	6.7	308
301	Exercise training increases electron and substrate shuttling proteins in muscle of overweight men and women with the metabolic syndrome. <i>Journal of Applied Physiology</i> , 2005, 98, 168-179.	2.5	52
302	Neuronal plasticity after spinal cord injury: identification of a gene cluster driving neurite outgrowth. <i>FASEB Journal</i> , 2005, 19, 153-154.	0.5	78
303	Decreased Asialotransferrin in Cerebrospinal Fluid of Patients with Childhood-Onset Ataxia and Central Nervous System Hypomyelination/Vanishing White Matter Disease. <i>Clinical Chemistry</i> , 2005, 51, 2031-2042.	3.2	43
304	Changes in Ubiquitin Proteasome Pathway Gene Expression in Skeletal Muscle With Exercise and Statins. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 2560-2566.	2.4	122
305	ACTN3 genotype is associated with increases in muscle strength in response to resistance training in women. <i>Journal of Applied Physiology</i> , 2005, 99, 154-163.	2.5	262
306	Prednisolone-induced changes in dystrophic skeletal muscle. <i>FASEB Journal</i> , 2005, 19, 1-23.	0.5	65

#	ARTICLE	IF	CITATIONS
307	NKG2A and CD56 Are Coexpressed on Activated TH2 but Not TH1 Lymphocytes. Human Immunology, 2005, 66, 1223-1234.	2.4	10
308	Elevated stearoyl-CoA desaturase-1 expression in skeletal muscle contributes to abnormal fatty acid partitioning in obese humans. Cell Metabolism, 2005, 2, 251-261.	16.2	326
309	Proteome Analysis of Skeletal Muscle From Obese and Morbidly Obese Women. Diabetes, 2005, 54, 1283-1288.	0.6	96
310	Genotype Associations With Increases In Blood Creatine Kinase And Myoglobin Following Intense Eccentric Exercise. Medicine and Science in Sports and Exercise, 2005, 37, S166-S167.	0.4	84
311	GENE SELECTION BY WEIGHTED FISHER CRITERION FOR MULTICLASS PREDICTION. , 2005, , .		1
312	Variability in muscle size and strength gain after unilateral resistance training. Medicine and Science in Sports and Exercise, 2005, 37, 964-72.	0.4	241
313	The PEPR GeneChip data warehouse, and implementation of a dynamic time series query tool (SGQT) with graphical interface. Nucleic Acids Research, 2004, 32, 578D-581.	14.5	47
314	Murine Cytomegalovirus Infection Increases Aortic Expression of Proatherosclerotic Genes. Circulation, 2004, 109, 893-897.	1.6	35
315	Functional Polymorphisms Associated with Human Muscle Size and Strength. Medicine and Science in Sports and Exercise, 2004, 36, 1132-1139.	0.4	62
316	Interactively optimizing signal-to-noise ratios in expression profiling: project-specific algorithm selection and detection p-value weighting in Affymetrix microarrays. Bioinformatics, 2004, 20, 2534-2544.	4.1	119
317	Balancing muscle hypertrophy and atrophy. Nature Medicine, 2004, 10, 584-585.	30.7	99
318	Constitutive activation of MAPK cascade in acute quadriplegic myopathy. Annals of Neurology, 2004, 55, 195-206.	5.3	114
319	Embryonic myogenesis pathways in muscle regeneration. Developmental Dynamics, 2004, 229, 380-392.	1.8	177
320	Deacetylase Inhibitors Increase Muscle Cell Size by Promoting Myoblast Recruitment and Fusion through Induction of Follistatin. Developmental Cell, 2004, 6, 673-684.	7.0	214
321	Novel Genetic Variation in Muscle Genes Correlated with Muscle Strength, Size and Response to Resistance Training (FAMuSS). Medicine and Science in Sports and Exercise, 2004, 36, S260.	0.4	1
322	Genetic Modifiers of Cerebrovascular Large Vessel Stenosis in Sickle Cell Anemia.. Blood, 2004, 104, 1658-1658.	1.4	1
323	Microarray Analysis of Peripheral Blood Monocytes in Sickle Cell Anemia Patients with Cerebrovascular Stenosis.. Blood, 2004, 104, 3570-3570.	1.4	0
324	Decreased Platelet Expression of MYL9 (Myosin Regulatory Light Chain Polypeptide) and Other Genes with Platelets Dysfunction and CBFA2 Mutation: Insights from Platelet Expression Profiling.. Blood, 2004, 104, 737-737.	1.4	1

#	ARTICLE	IF	CITATIONS
325	Gene profiling in spinal cord injury shows role of cell cycle in neuronal death. <i>Annals of Neurology</i> , 2003, 53, 454-468.	5.3	261
326	In vivo filtering of in vitro expression data reveals MyoD targets. <i>Comptes Rendus - Biologies</i> , 2003, 326, 1049-1065.	0.2	40
327	Sir2 Regulates Skeletal Muscle Differentiation as a Potential Sensor of the Redox State. <i>Molecular Cell</i> , 2003, 12, 51-62.	9.7	542
328	Expression profiling and pharmacogenomics of muscle and muscle disease. <i>Current Opinion in Pharmacology</i> , 2003, 3, 309-316.	3.5	8
329	Molecular responses of human muscle to eccentric exercise. <i>Journal of Applied Physiology</i> , 2003, 95, 2485-2494.	2.5	120
330	Patterns of global gene expression in rat skeletal muscle during unloading and low-intensity ambulatory activity. <i>Physiological Genomics</i> , 2003, 13, 157-167.	2.3	91
331	Future Research Directions in Acute Lung Injury. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2003, 167, 1027-1035.	5.6	489
332	New molecular research technologies in the study of muscle disease. <i>Current Opinion in Rheumatology</i> , 2003, 15, 698-707.	4.3	8
333	Skeletal muscle dictates the fibrinolytic state after exercise training in overweight men with characteristics of metabolic syndrome. <i>Journal of Physiology</i> , 2003, 548, 401-410.	2.9	56
334	Gene Expression Profiling in DQA1*0501+ Children with Untreated Dermatomyositis: A Novel Model of Pathogenesis. <i>Journal of Immunology</i> , 2002, 168, 4154-4163.	0.8	220
335	Slug Is a Novel Downstream Target of MyoD. <i>Journal of Biological Chemistry</i> , 2002, 277, 30091-30101.	3.4	97
336	Expression profiling reveals metabolic and structural components of extraocular muscles. <i>Physiological Genomics</i> , 2002, 9, 71-84.	2.3	94
337	Integrin $\alpha 7 \beta 1$ in Muscular Dystrophy/Myopathy of Unknown Etiology. <i>American Journal of Pathology</i> , 2002, 160, 2135-2143.	3.8	59
338	A web-accessible complete transcriptome of normal human and DMD muscle. <i>Neuromuscular Disorders</i> , 2002, 12, S125-S141.	0.6	156
339	Collaborative translational research leading to multicenter clinical trials in Duchenne muscular dystrophy: the Cooperative International Neuromuscular Research Group (CINRG). <i>Neuromuscular Disorders</i> , 2002, 12, S147-S154.	0.6	13
340	Clarifying the boundaries between the inflammatory and dystrophic myopathies: insights from molecular diagnostics and microarrays. <i>Rheumatic Disease Clinics of North America</i> , 2002, 28, 743-757.	1.9	52
341	Functional characteristics of dystrophic skeletal muscle: insights from animal models. <i>Journal of Applied Physiology</i> , 2002, 93, 407-417.	2.5	94
342	Development and production of an oligonucleotide MuscleChip: use for validation of ambiguous ESTs. <i>BMC Bioinformatics</i> , 2002, 3, 33.	2.6	8

#	ARTICLE	IF	CITATIONS
343	Sources of variability and effect of experimental approach on expression profiling data interpretation. BMC Bioinformatics, 2002, 3, 4.	2.6	162
344	Response of rat muscle to acute resistance exercise defined by transcriptional and translational profiling. Journal of Physiology, 2002, 545, 27-41.	2.9	127
345	Genetic medicine and the muscular dystrophies: triumphs and tribulations. Developmental Medicine and Child Neurology, 2002, 44, 136-140.	2.1	0
346	Genetic medicine and the muscular dystrophies: triumphs and tribulations. Developmental Medicine and Child Neurology, 2002, 44, 136.	2.1	0
347	Molecular pathophysiology and targeted therapeutics for muscular dystrophy. Trends in Pharmacological Sciences, 2001, 22, 465-470.	8.7	74
348	Massive muscle cell degeneration in the early stage of merosin-deficient congenital muscular dystrophy. Neuromuscular Disorders, 2001, 11, 350-359.	0.6	54
349	Molecular Diagnosis and Genetic Counseling of the Manifesting Carrier of Duchenne Muscular Dystrophy. , 2001, , 173-188.		0
350	Confocal analysis of the dystrophin protein complex in muscular dystrophy. Muscle and Nerve, 2001, 24, 262-272.	2.2	18
351	Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations. Annals of Neurology, 2001, 49, 706-711.	5.3	238
352	Plasma membrane cytoskeleton of muscle: a fine structural analysis. , 2000, 48, 131-141.		23
353	Private β - and γ -sarcoglycan gene mutations: Evidence of a founder effect in Northern Italy. Human Mutation, 2000, 16, 13-17.	2.5	19
354	Expression Profiling in the Muscular Dystrophies. Journal of Cell Biology, 2000, 151, 1321-1336.	5.2	448
355	Unique PABP2 mutations in β -Cajuns β suggest multiple founders of oculopharyngeal muscular dystrophy in populations with French ancestry. , 1999, 86, 477-481.		27
356	Herpes simplex virus vector-mediated dystrophin gene transfer and expression in MDX mouse skeletal muscle. Journal of Gene Medicine, 1999, 1, 280-289.	2.8	69
357	Prenatal diagnosis in a family affected with β -sarcoglycan muscular dystrophy. Neuromuscular Disorders, 1999, 9, 323-325.	0.6	3
358	Counting muscular dystrophies in the post-molecular census. Journal of the Neurological Sciences, 1999, 164, 3-6.	0.6	10
359	Muscular Dystrophy. Archives of Pathology and Laboratory Medicine, 1999, 123, 1050-1052.	2.5	20
360	Mutations in the integrin α 7 gene cause congenital myopathy. Nature Genetics, 1998, 19, 94-97.	21.4	355

#	ARTICLE	IF	CITATIONS
361	Muscle maturation: implications for gene therapy. Trends in Molecular Medicine, 1998, 4, 214-220.	2.6	41
362	A dystrophin missense mutation showing persistence of dystrophin and dystrophin-associated proteins yet a severe phenotype. Annals of Neurology, 1998, 44, 971-976.	5.3	44
363	Role of the nerve in determining fetal skeletal muscle phenotype. , 1998, 211, 177-190.		37
364	Homozygous β -sarcoglycan mutation in two siblings: One asymptomatic and one steroid-responsive mild limb-girdle muscular dystrophy patient. Muscle and Nerve, 1998, 21, 769-775.	2.2	71
365	Molecular Basis of Neuromuscular Disease. Physical Medicine and Rehabilitation Clinics of North America, 1998, 9, 49-81.	1.3	13
366	Muscular Dystrophies. , 1998, , 859-863.		0
367	Mutations in the Sarcoglycan Genes in Patients with Myopathy. New England Journal of Medicine, 1997, 336, 618-625.	27.0	223
368	Mutations in the β -sarcoglycan gene are a rare cause of autosomal recessive limb-girdle muscular dystrophy (LGMD2). Neurogenetics, 1997, 1, 49-58.	1.4	57
369	Asymptomatic dystrophinopathy. , 1997, 69, 261-267.		34
370	Recruitment of mast cells to muscle after mild damage. Journal of the Neurological Sciences, 1996, 135, 10-17.	0.6	52
371	β -Sarcoglycan (adhalin) deficiency: complete deficiency patients are 5% of childhood-onset dystrophin-normal muscular dystrophy and most partial deficiency patients do not have gene mutations. Journal of the Neurological Sciences, 1996, 140, 30-39.	0.6	36
372	Autosomal recessive muscular dystrophy and mutations of the sarcoglycan complex. Neuromuscular Disorders, 1996, 6, 475-482.	0.6	43
373	Clinical and Histopathological Features of Abnormalities of the Dystrophin-Based Membrane Cytoskeleton. Brain Pathology, 1996, 6, 49-61.	4.1	35
374	Congenital muscular dystrophy with primary laminin α 2 (merosin) deficiency presenting as inflammatory myopathy. Annals of Neurology, 1996, 40, 782-791.	5.3	119
375	X-inactivation patterns in female Leber's hereditary optic neuropathy patients do not support a strong X-linked determinant. , 1996, 61, 356-362.		36
376	Genetic counseling of isolated carriers of Duchenne muscular dystrophy. , 1996, 63, 573-580.		28
377	Extensive genetic heterogeneity in the "pure" form of autosomal dominant familial spastic paraplegia (Stri β 2mpell's disease). , 1996, 19, 1435-1438.		5
378	X-inactivation patterns in female Leber's hereditary optic neuropathy patients do not support a strong X-linked determinant. American Journal of Medical Genetics Part A, 1996, 61, 356-362.	2.4	1

#	ARTICLE	IF	CITATIONS
379	Hyperkalemic periodic paralysis with cardiac dysrhythmia: A novel sodium channel mutation?. Annals of Neurology, 1995, 37, 408-411.	5.3	18
380	Primary adhalin deficiency as a cause of muscular dystrophy in patients with normal dystrophin. Annals of Neurology, 1995, 38, 367-372.	5.3	65
381	Î²â€“sarcoglycan (A3b) mutations cause autosomal recessive muscular dystrophy with loss of the sarcoglycan complex. Nature Genetics, 1995, 11, 266-273.	21.4	438
382	VOLTAGE-GATED ION CHANNELOPATHIES: Inherited Disorders Caused by Abnormal Sodium, Chloride, and Calcium Regulation in Skeletal Muscle. Annual Review of Medicine, 1995, 46, 431-441.	12.2	44
383	Medium Chain Acyl-CoA Dehydrogenase Deficiency in Pennsylvania: Neonatal Screening Shows High Incidence and Unexpected Mutation Frequencies. Pediatric Research, 1995, 37, 675-678.	2.3	156
384	Phospholipase A2 activity in dystrophinopathies. Neuromuscular Disorders, 1995, 5, 193-199.	0.6	44
385	Overexcited or inactive: Ion channels in muscle disease. Cell, 1995, 80, 681-686.	28.9	140
386	Molecular Diagnosis and Modern Management of Duchenne Muscular Dystrophy. Neurologic Clinics, 1994, 12, 699-725.	1.8	22
387	The rumpshaker mutation in spastic paraplegia. Nature Genetics, 1994, 7, 351-352.	21.4	158
388	Dystrophin associated proteins fail in filling dystrophin's shoes. Nature Genetics, 1994, 8, 311-312.	21.4	7
389	A role for mast cells in the progression of Duchenne muscular dystrophy?. Journal of the Neurological Sciences, 1994, 122, 44-56.	0.6	100
390	Dystrophin-deficient myofibers are vulnerable to mast cell granule-induced necrosis. Neuromuscular Disorders, 1994, 4, 325-333.	0.6	66
391	In utero fetal muscle biopsy for the diagnosis of Duchenne muscular dystrophy in a female fetus â€œsuddenly at riskâ€ American Journal of Medical Genetics Part A, 1993, 46, 309-312.	2.4	19
392	Duchenne-Becker Muscular Dystrophy and the Nondystrophic Myotonias. Archives of Neurology, 1993, 50, 1227.	4.5	29
393	Response to Letter by Law. Cell Transplantation, 1993, 2, 438-438.	2.5	0
394	Genotype/phenotype correlations in Duchenne/Becker dystrophy. , 1993, 3, 12-36.		31
395	Dystrophin deficiency causes lethal muscle hypertrophy in cats. Journal of the Neurological Sciences, 1992, 110, 149-159.	0.6	120
396	Periodic paralysis in Quarter Horses: a sodium channel mutation disseminated by selective breeding. Nature Genetics, 1992, 2, 144-147.	21.4	224

#	ARTICLE	IF	CITATIONS
397	X inactivation and dystrophin studies in a t(X;12) female: Evidence for biochemical normalization in Duchenne muscular dystrophy carriers. American Journal of Medical Genetics Part A, 1992, 43, 1012-1015.	2.4	17
398	Additional dystrophin fragment in Becker muscular dystrophy may result from proteolytic cleavage at deletion junctions. American Journal of Medical Genetics Part A, 1992, 44, 378-381.	2.4	9
399	Recent advances in dystrophin research. Current Opinion in Neurobiology, 1991, 1, 420-429.	4.2	25
400	In utero fetal muscle biopsy for the diagnosis of Duchenne muscular dystrophy. American Journal of Obstetrics and Gynecology, 1991, 165, 728-732.	1.3	40
401	Molecular diagnostics of Duchenne/Becker dystrophy: New additions to a rapidly expanding literature. Journal of the Neurological Sciences, 1991, 101, 129-132.	0.6	8
402	Chapter 8 The Animal Models of Duchenne Muscular Dystrophy: Windows on the Pathophysiological Consequences of Dystrophin Deficiency. Current Topics in Membranes, 1991, , 113-154.	0.9	49
403	A Met-to-Val mutation in the skeletal muscle Na ⁺ channel α -subunit in hyperkalaemic periodic paralysis. Nature, 1991, 354, 387-389.	27.8	356
404	Muscle histology in becker muscular dystrophy. Muscle and Nerve, 1991, 14, 1067-1073.	2.2	27
405	Discordance of muscular dystrophy in monozygotic female twins: Evidence supporting asymmetric splitting of the inner cell mass in a manifesting carrier of Duchenne dystrophy. American Journal of Medical Genetics Part A, 1991, 40, 354-364.	2.4	76
406	Is the carboxyl-terminus of dystrophin required for membrane association? A novel, severe case of duchenne muscular dystrophy. Annals of Neurology, 1991, 30, 605-610.	5.3	88
407	Quadriceps myopathy: Forme fruste of Becker muscular dystrophy. Annals of Neurology, 1990, 28, 634-639.	5.3	82
408	Duchenne and Becker Muscular Dystrophies: Genetics, Prenatal Diagnosis, and Future Prospects. Clinics in Perinatology, 1990, 17, 845-863.	2.1	23
409	Somatic reversion/suppression of the mouse mdx phenotype in vivo. Journal of the Neurological Sciences, 1990, 99, 9-25.	0.6	278
410	Human molecular genetics and the elucidation of the primary biochemical defect in duchenne muscular dystrophy. Cytoskeleton, 1989, 14, 163-168.	4.4	5
411	Dystrophin abnormalities in Duchenne/Becker muscular dystrophy. Neuron, 1989, 2, 1019-1029.	8.1	320
412	Immunoelectron microscopic localization of dystrophin in myofibres. Nature, 1988, 333, 863-866.	27.8	450
413	The homologue of the Duchenne locus is defective in X-linked muscular dystrophy of dogs. Nature, 1988, 334, 154-156.	27.8	385
414	Proteolytic fragment or new gene product?. Nature, 1988, 336, 210-210.	27.8	12

#	ARTICLE	IF	CITATIONS
415	Characterization of Dystrophin in Muscle-Biopsy Specimens from Patients with Duchenne's or Becker's Muscular Dystrophy. New England Journal of Medicine, 1988, 318, 1363-1368.	27.0	911
416	Molecular biology of Duchenne muscular dystrophy. Trends in Neurosciences, 1988, 11, 480-484.	8.6	21
417	Cell and fiber type distribution of dystrophin. Neuron, 1988, 1, 411-420.	8.1	210
418	Duchenne muscular dystrophy: Deficiency of dystrophin at the muscle cell surface. Cell, 1988, 54, 447-452.	28.9	592
419	Dystrophin: The protein product of the duchenne muscular dystrophy locus. Cell, 1987, 51, 919-928.	28.9	4,277
420	Regional localization of the murine Duchenne muscular dystrophy gene on the mouse X chromosome. Somatic Cell and Molecular Genetics, 1987, 13, 671-678.	0.7	44
421	Subcellular fractionation of dystrophin to the triads of skeletal muscle. Nature, 1987, 330, 754-758.	27.8	318